Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and Paclitaxel in Prior Taxane-Treated Solid Tumors
NCT05554341Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in solid tumor, sponsored by National Cancer Institute. Started Jul 2023; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05554341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554341.